Actively Recruiting
Dexamethasone Palmitate for PONV After Craniotomy
Led by Beijing Tiantan Hospital · Updated on 2025-09-23
500
Participants Needed
1
Research Sites
100 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Dexamethasone is almost one of the most commonly used drugs for postoperative nausea and vomiting (PONV) prevention. However, PONV is still a complex problem to be solved; for example, even with preoperative dexamethasone administration, there are still some patients undergoing craniotomy still experience PONV within 24 hours postoperatively. Compared to dexamethasone, dexamethasone palmitate has a long-lasting anti-inflammatory effect, 2-5 times that of traditional water-soluble dexamethasone, with fewer adverse effects. This trial aims to assess the effect and safety of preoperative dexamethasone palmitate on PONV after craniotomy.
CONDITIONS
Official Title
Dexamethasone Palmitate for PONV After Craniotomy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 to 65 years
- Provide written informed consent
- Scheduled for elective craniotomy under general anesthesia
You will not qualify if you...
- Known allergy to dexamethasone
- Use of systemic glucocorticoids within 3 months before trial
- History of severe heart disease, liver or kidney failure, or systemic rheumatic diseases
- Cognitive impairment or severe mental illness
- Uncontrolled diabetes or infectious diseases
- Pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fang Luo
Beijing, China, 100050
Actively Recruiting
Research Team
F
Fang Luo
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here